(KVUE) Kenvue - NYSE
Sector: Consumer Defensive | Industry: Household & Personal Products | Exchange: NYSE (USA) | Market Cap: 34.003m USD | Total Return: -13.8% in 12m
Avg Turnover: 381M
EPS Trend: -87.5%
Qual. Beats: 1
Rev. Trend: -75.9%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Confidence
Kenvue Inc. is a global consumer health company operating across three primary segments: Self Care, Skin Health and Beauty, and Essential Health. Headquartered in New Jersey, the firm maintains a diverse portfolio of legacy brands including Tylenol, Listerine, Neutrogena, and Band-Aid. Its business model focuses on high-volume, repeat-purchase products distributed through retail and digital channels worldwide.
The consumer health sector is characterized by defensive revenue streams, as demand for over-the-counter medicines and personal hygiene products remains relatively inelastic during economic downturns. Spun off from Johnson & Johnson in 2023, Kenvue operates as a pure-play entity in a market where brand equity and regulatory compliance serve as significant barriers to entry. You can assess the intrinsic valuation of this stock by visiting ValueRay.
- Self Care segment volume growth driven by allergy and pain medication demand
- Input cost inflation and supply chain efficiency impact gross operating margins
- Potential talc-related litigation liabilities inherited from Johnson & Johnson spin-off
- Marketing spend effectiveness for Neutrogena and Aveeno determines market share gains
- Emerging market expansion offsets slowing consumer health demand in North America
| Net Income: 1.62b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.27 > 1.0 |
| NWC/Revenue: -0.66% < 20% (prev -6.25%; Δ 5.59% < -1%) |
| CFO/TA 0.08 > 3% & CFO 2.26b > Net Income 1.62b |
| Net Debt (7.73b) to EBITDA (3.26b): 2.37 < 3 |
| Current Ratio: 0.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.92b) vs 12m ago -0.16% < -2% |
| Gross Margin: 58.37% > 18% (prev 58.06%; Δ 0.31% > 0.5%) |
| Asset Turnover: 57.59% > 50% (prev 58.28%; Δ -0.69% > 0%) |
| Interest Coverage Ratio: 6.85 > 6 (EBIT TTM 2.69b / Interest Expense TTM 393.0m) |
| A: -0.00 (Total Current Assets 5.79b - Total Current Liabilities 5.90b) / Total Assets 26.9b |
| B: -0.00 (Retained Earnings -128.0m / Total Assets 26.9b) |
| C: 0.10 (EBIT TTM 2.69b / Avg Total Assets 26.6b) |
| D: 0.65 (Book Value of Equity 10.6b / Total Liabilities 16.2b) |
| Altman-Z'' = 1.33 = BB |
| DSRI: 0.89 (Receivables 2.50b/2.82b, Revenue 15.3b/15.3b) |
| GMI: 0.99 (GM 58.06% / 58.37%) |
| AQI: 0.99 (AQ_t 0.70 / AQ_t-1 0.71) |
| SGI: 1.00 (Revenue 15.3b / 15.3b) |
| TATA: -0.02 (NI 1.62b - CFO 2.26b) / TA 26.9b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of June 09, 2026, the stock is trading at USD 17.55 with a total of 20,216,820 shares traded.
Over the past week, the price has changed by +1.15%,
over one month by +0.97%,
over three months by -2.19% and
over the past year by -13.78%.
Kenvue has received a consensus analysts rating of 3.42. Therefore, it is recommended to hold KVUE.
- StrongBuy: 3
- Buy: 2
- Hold: 14
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19.5 | 11.1% |
P/E Trailing = 21.0833
P/E Forward = 14.881
P/S = 2.2236
P/B = 3.0552
P/EG = 1.4164
Revenue TTM = 15.3b USD
EBIT TTM = 2.69b USD
EBITDA TTM = 3.26b USD
Long Term Debt = 7.07b USD (from longTermDebt, last quarter)
Short Term Debt = 1.59b USD (from shortTermDebt, last quarter)
Debt = 8.80b USD (from shortLongTermDebtTotal, last quarter) + Leases 141.0m
Net Debt = 7.73b USD (calculated: Debt 8.80b - CCE 1.07b)
Enterprise Value = 41.7b USD (34.0b + Debt 8.80b - CCE 1.07b)
Interest Coverage Ratio = 6.85 (Ebit TTM 2.69b / Interest Expense TTM 393.0m)
EV/FCF = 22.89x (Enterprise Value 41.7b / FCF TTM 1.82b)
FCF Yield = 4.37% (FCF TTM 1.82b / Enterprise Value 41.7b)
FCF Margin = 11.92% (FCF TTM 1.82b / Revenue TTM 15.3b)
Net Margin = 10.61% (Net Income TTM 1.62b / Revenue TTM 15.3b)
Gross Margin = 58.37% ((Revenue TTM 15.3b - Cost of Revenue TTM 6.37b) / Revenue TTM)
Gross Margin QoQ = 58.89% (prev 56.53%)
Tobins Q-Ratio = 1.55 (Enterprise Value 41.7b / Total Assets 26.9b)
Interest Expense / Debt = 4.46% (Interest Expense 393.0m / Debt 8.80b)
Taxrate = 26.71% (591.0m / 2.21b)
NOPAT = 1.97b (EBIT 2.69b * (1 - 26.71%))
Current Ratio = 0.98 (Total Current Assets 5.79b / Total Current Liabilities 5.90b)
Debt / Equity = 0.83 (Debt 8.80b / totalStockholderEquity, last quarter 10.6b)
Debt / EBITDA = 2.37 (Net Debt 7.73b / EBITDA 3.26b)
Debt / FCF = 4.24 (Net Debt 7.73b / FCF TTM 1.82b)
Total Stockholder Equity = 10.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.11% (Net Income 1.62b / Total Assets 26.9b)
RoE = 15.18% (Net Income TTM 1.62b / Total Stockholder Equity 10.7b)
RoCE = 15.17% (EBIT 2.69b / Capital Employed (Equity 10.7b + L.T.Debt 7.07b))
RoIC = 9.06% (NOPAT 1.97b / Invested Capital 21.8b)
WACC = 4.78% (E(34.0b)/V(42.8b) * Re(5.17%) + D(8.80b)/V(42.8b) * Rd(4.46%) * (1-Tc(0.27)))
Discount Rate = 5.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 23.00 | Cagr: 0.16%
[DCF] Terminal Value 77.97% ; FCFF base≈1.67b ; Y1≈1.92b ; Y5≈2.82b
[DCF] Fair Price = 18.11 (EV 42.5b - Net Debt 7.73b = Equity 34.8b / Shares 1.92b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -87.45 | EPS CAGR: -19.32% | SUE: 2.06 | # QB: 1
Revenue Correlation: -75.94 | Revenue CAGR: -0.94% | SUE: 0.78 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.32 | Chg30d=+3.65% | Revisions=+45% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.30 | Chg30d=+2.02% | Revisions=+27% | Analysts=9
EPS current Year (2026-12-31): EPS=1.19 | Chg30d=+4.91% | Revisions=+60% | GrowthEPS=+10.1% | GrowthRev=+3.3%
EPS next Year (2027-12-31): EPS=1.24 | Chg30d=+2.58% | Revisions=+43% | GrowthEPS=+4.0% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: +60%